96% of IIMM patients have abnormal Freelite® light chain concentrations or kappa/lambda ratio
Some 82% of patients with Multiple Myeloma produce a detectable monoclonal protein of intact immunoglobulin heavy chain type G, A, M, D or E and either light chain kappa or lambda. This paraprotein can be used as a serum marker for diagnosis and levels can be monitored during treatment to assess efficacy.
Measurement of serum free light chains with Freelite® has shown that 96% of patients with Intact Immunoglobulin Multiple Myeloma also have abnormal light chain concentration or abnormal kappa/lambda (κ/λ) ratios in addition to the intact immunoglobulin.1
Concentrations of Freelite® serum free light chains in 314 patients with IgG Myeloma compared with 282 normal sera.
Concentrations of Freelite® serum free light chains in 142 IgA, 36 IgD and 5 IgE Myeloma patients compared with 282 normal sera.